Ishida H, Koyama I, Sawada T, Utsumi K, Murakami T, Sannomiya A, Tsuji K, Yoshimura N, Tojimbara T, Nakajima I, Tanabe K, Yamaguchi Y, Fuchinoue S, Takahashi K, Teraoka S, Ito K, Toma H, Agishi T
Department of Surgery III, Tokyo Women's Medical University, Japan.
Transplantation. 2000 Aug 27;70(4):681-5. doi: 10.1097/00007890-200008270-00024.
A shortage of organ donors for transplantation has become a serious problem throughout the world. To overcome this problem, transplantations across ABO blood barriers have been performed with some success. In general, however, the graft survival rate for transplantation with ABO incompatibility is lower than that of transplantation with ABO compatibility. Unfortunately, the mechanism by which isohemagglutinins might injure an ABO-incompatible graft remains uncertain. Here, the pre- and posttransplantation anti-AB titers in patients who received transplants from ABO-incompatible living donors are reviewed and the pathological findings are compared.
One hundred and one patients underwent ABO-incompatible living related kidney transplantation (i-LKT) between January 1989 and October 1999 at our hospital. Plasmapheresis and immunoadsorption were performed in all of the i-LKT patients before the transplantation to remove anti-AB antibodies. A splenectomy was also performed during the operation, followed by the local irradiation of the graft with a dose of 150 rad. The anti-AB titers and pathological findings for 93 i-LKT patients, excluding 8 patients who died, were then examined.
Immediately after the i-LKT, the anti-AB titer dropped rapidly to below 1:4 in all 93 cases. Seventy of patients (70/93, 75%) showed no elevation in their anti-AB titer during their follow-up. However, the remaining 23 patients (23/93, 25%) showed a significant elevation of their anti-AB titer to over 1:16. Sixteen of these patients (16/93, 17%) exhibited an anti-AB titer of over 1:32. Out of these 16 patients, 11 patients (11/16, 69%) lost their grafts. The anti-AB titer in the remaining five patients (5/16, 31%) spontaneously decreased without any special treatment. Seven patients (7/93, 8%) exhibited an elevated titer of 1:16. Out of these patients, only one patient (1/7, 14%) lost his graft. The elevated titers in the remaining six patients (6/7, 86%) eventually decreased. The graft function improved in patients whose elevated anti-AB titers eventually decreased. Control patients (ABO-compatible kidney transplant patients) showed a normal elevation of their titer values compared with preoperative titers. Pathological findings showed severe humoral rejections in all cases with high anti-AB titers that lost grafts. Humoral rejection was also detected in most of the patients whose anti-AB titer was elevated to over 1:16 after the transplantation, but excellent renal function was resumed once the titers decreased to below 1:4.
In 23 out of 93 i-LKT patients (25%), the anti-AB titers were significantly elevated after the splenectomy. In view of other reports of i-LKT without splenectomy, we feel that a splenectomy in i-LKT patients might be unnecessary. Pathological evidence suggests that the decrease in the anti-AB titer after transplantation might be the net result of plasmapheresis before the operation and the adsorption of antibodies to the endothelium of the transplanted organ after the operation, neither of which is influenced by a splenectomy.
移植器官供体短缺已成为全球范围内的一个严重问题。为克服这一问题,已开展了一些跨越ABO血型屏障的移植手术并取得了一定成功。然而,一般来说,ABO血型不相容移植的移植物存活率低于ABO血型相容移植。不幸的是,同种血凝素可能损伤ABO血型不相容移植物的机制仍不明确。在此,对接受ABO血型不相容活体供体移植患者的移植前后抗AB滴度进行回顾,并比较病理结果。
1989年1月至1999年10月期间,我院有101例患者接受了ABO血型不相容亲属活体肾移植(i-LKT)。所有i-LKT患者在移植前均进行了血浆置换和免疫吸附以去除抗AB抗体。手术期间还进行了脾切除术,随后对移植物进行150拉德剂量的局部照射。然后检查了93例i-LKT患者(不包括8例死亡患者)的抗AB滴度和病理结果。
i-LKT术后,所有93例患者的抗AB滴度立即迅速降至1:4以下。70例患者(70/93,75%)在随访期间抗AB滴度未升高。然而,其余23例患者(23/93,25%)的抗AB滴度显著升高至1:16以上。其中16例患者(16/93,17%)的抗AB滴度超过1:32。在这16例患者中,11例患者(11/16,69%)失去了移植物。其余5例患者(5/16,31%)的抗AB滴度未经任何特殊治疗自行下降。7例患者(7/93,8%)的滴度升高至1:16。在这些患者中,只有1例患者(1/7,14%)失去了移植物。其余6例患者(6/7,86%)升高的滴度最终下降。抗AB滴度最终下降的患者移植物功能得到改善。对照患者(ABO血型相容肾移植患者)与术前滴度相比,滴度值呈正常升高。病理结果显示,所有抗AB滴度高且失去移植物的病例均有严重的体液排斥反应。大多数移植后抗AB滴度升高至1:16以上的患者也检测到体液排斥反应,但一旦滴度降至1:4以下,肾功能即可恢复良好。
93例i-LKT患者中有23例(25%)在脾切除术后抗AB滴度显著升高。鉴于其他未行脾切除术的i-LKT报告,我们认为i-LKT患者可能无需进行脾切除术。病理证据表明,移植后抗AB滴度的下降可能是术前血浆置换以及术后抗体吸附到移植器官内皮细胞的综合结果,两者均不受脾切除术的影响。